摘要
目的探讨双途径化疗[经DDS泵门静脉化疗（PVC）联合肝动脉插管化疗栓塞（TACE）]预防术后肝细胞肝癌和门静脉癌栓复发的临床疗效及安全性。方法将2009年1月至2011年1月威海市立医院收治的87例有手术指征肝癌合并门静脉癌栓患者随机分成3组，切除肿瘤并取癌栓后A组行TACE、B组行经DDS泵PVC，C组行经DDS泵PVC联合TACE。随访3组患者术后6个月及1、2、3年无瘤生存率及累积生存率，并进行统计学分析。结果术后6个月及1、2、3年无瘤生存率及累积生存率C组均高于A、B组。术后6个月、1年时差异无统计学意义（P〉0．05）；术后2、3年时差异有统计学意义（P〈0．01）。上消化道出血的发生率C组与A、B两组问差异无统计学意义（P〉0．05）。结论肝细胞肝癌合并门静脉癌栓患者手术切除肿瘤并取癌栓后，行经DDS泵PVC联合TACE较单独PVC或TACE有效提高其远期无瘤生存率及累计生存率，且不增加上消化道出血的发生率。
Objective To study the achievements and safety of Transcatheter arterial chemoembolization （TACE） associated Portal Vein Chemo-therapy （PVC） perdrug delivery system （DDS） program in preventing the recurrence of hepatic cell cancer （HCC） and Portal Vein Tumor Thrombus （PVTT）. Methods 97 cases with HCC and PVTT were treated from Januay 2009 to January 2011. Patients with tumor or tumor thrombus were resected on all the cases and randomly divided into 3 groups. TACE, PVC per-DDS TACE and PVC per-DDS were given to group A, group B, and group C, respectively. Patients in the 3 groups were followed and compared on the Disease Free Survivals （DFS） and the accumulative survival rates, at 6 months, 1 year and 2 years after the operation. Results After the surgery was completed in June, the 1-year, 2-year, 3-year survival rates and cummulative survival rate in group C was higher than in group A or group. Significant differences did no appeare in June but did show in 1 year after the surgery （P〉0.05） as well as in both 2 and 3 years, after the surgery （P〈0.01）. Conclusion Patients with HCC and PVTT, the TACE chemotherapy in association with PVC per-DDS could increase both the DFSs and accumulative survival rates, when compared to the either single TACE or PVC per-DDS, after the tumor or tumor thrombus were resected.
出处
《中华流行病学杂志》
CAS
CSCD
北大核心
2012年第11期1181-1183,共3页
Chinese Journal of Epidemiology
关键词
肝细胞肝癌
门静脉癌栓
肝动脉插管化疗栓塞
门静脉化疗
Hepatic cell cancer
Portal vein tumor thrombus
Transcatheter arterial chemoembolization
Portal vein chemotherapy
